STAT2 Knockout cell line (A549)

Ubigene gene knockout cell lines mediated by optimized CRISPR-Cas9 technology provide reliable in vitro models for investigating gene function, signaling pathways, disease mechanisms, and therapeutic targets.

STAT2 (signal transducer and activator of transcription 2) encodes a transcription factor of the STAT family that mediates cytokine and growth factor signaling. Following interferon stimulation, STAT2 forms a complex with STAT1 and IRF9 to constitute ISGF3, which activates interferon-responsive gene transcription. STAT2 therefore plays a central role in interferon signaling and innate antiviral immunity.

A549 is a human lung cancer cell line established in 1972 from an explanted lung tumor of a 58-year-old male patient. The cells exhibit characteristics of alveolar type II pulmonary epithelial cells, including the ability to synthesize lecithin through the cytidine diphosphocholine pathway. A549 cells have been described as originating from lung adenocarcinoma and are widely used as a model for studying lung cancer biology, pulmonary epithelial function, drug responses, and respiratory-related research.

Comprehensive quality control includes STR authentication, sterility testing (bacteria and fungi), and mycoplasma screening to ensure purity and performance. Genotype is confirmed by two rounds of PCR and Sanger sequencing, and complete validation reports are provided for make-to-order products.